It is found that losartan, a high blood pressure drug, may improve the effectiveness of chemotherapy drugs for ovarian cancer

Recently, a new study from the research team of Massachusetts General Hospital (MGH) found that losartan, a high blood pressure drug (http:// targeting the Angiotension signaling pathway, may improve the effectiveness of chemotherapy drugs used to treat ovarian cancer Previous studies by the same research team found that losartan had similar effects in animal models of breast and pancreatic cancer, and related experimental therapies are currently in clinical phase II The researchers say that the extracellular matrix itself can prevent the penetration of high molecular weight drugs into the tumor, and the signal transduction of angiotensin helps the formation of the matrix Because of the increased level of an important enzyme in the angiotensin pathway and its association with poor prognosis of ovarian cancer, they studied whether losartan can improve the prognosis of animal models of ovarian cancer by reducing fibrosis In a series of experiments in two mouse models, the researchers found that losartan treatment reduced extracellular matrix content and solid stress in ovarian tumors, and increased blood supply (http:// , oxygen level and drug delivery; based on the mathematical model prediction of tumor physiology, adding losartan to intravenous or intraperitoneal injection of low molecular weight and high molecular weight cancer treatment can improve the results; adding losartan to chemotherapy drug paclitaxel treatment can enhance the antitumor effect of intraperitoneal injection of paclitaxel, reduce the accumulation of ascites, ascites, significantly reduce Quality of life of patients; losartan consumes extracellular matrix by inducing the expression of anti fibrosis miRNA molecules, which can be used as biomarkers of response or resistance to chemotherapy.